PLEASE REFER TO THE SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL PRESCRIBING INFORMATION.

NAME OF THE MEDICINAL PRODUCT: Effercitrate Tablets.

PRESENTATION: White circular, biconcave effervescent tablets. When dissolved in water, the solution will contain the equivalent of 1.5g potassium citrate and 0.25g citric acid.

INDICATIONS: For the treatment of cystitis, symptoms of cystitis and as an initial therapy in mild symptomatic cystitis prior to an MSU result. Confirmed bacterial infections should be treated with an appropriate course of an antibacterial agent.

DOSAGE AND ADMINISTRATION: For oral administration. Adults and Children over 6 years*:* Two tablets to be dissolved in a glass of water up to three times daily. Children under 6 years*:* Not recommended*.* Elderly*:* As adult dose*.* Dosing should ensure and maintain the urine to be alkaline.

CONTRAINDICATIONS: Hyperkalaemia from any cause, renal dysfunction (particularly with oliguria), ventricular arrhythmias, untreated Addison's disease and acute dehydration. Contraindicated in known hypersensitivity to potassium citrate, citric acid or any of the other ingredients.

WARNINGS AND PRECAUTIONS: Caution should be observed in patients with kidney disease, hypertension or heart disease. Use with caution in elderly patients as potassium excretion is reduced, increasing the risk of hyperkalaemia. If symptoms persist or worsen after 4 days, patients should seek medical advice.

INTERACTIONS: Do not co-administer with other potassium containing medicines, potassium sparing diuretics (eg. amiloride and triamterene), aldosterone antagonists (eg. spironolactone) or other medicines that increase potassium levels (eg. angiotensin-II receptor antagonists, ACE inhibitors, aliskiren, cyclosporine and tacrolimus). The activity of cardiac glycosides may be affected. In patients with acidosis, the acid-base balance should be monitored. In patients with hypertension, correction of hypokalaemia may lower blood pressure. Citrates may alter the urinary excretion of a number of drugs such as salicylates, tetracyclines and barbiturates, and prolong the half-life of basic drugs such as sympathomimetics and stimulants. The anti-bacterial activity of nitrofurantoin and methenamine is diminished.

FERTILITY, PREGNANCY AND LACTATION: Consultation with a physician prior to use is advised.

UNDESIRABLE EFFECTS: Gastric irritation may occur. The tablets should always be well diluted with water. Gastric effects may be minimised by taking with, or after meals.

BASIC NHS COST: Effercitrate Tablets (Tube of 12 tablets) - £6.29

LEGAL CATEGORY: GSL

LICENCE NUMBER: PL 16794/0009

MA HOLDER: Cambridge Healthcare Supplies Ltd, Unit 1 Chestnut Drive, Wymondham, Norfolk, NR18 9SB.

DATE OF PREPARATION: November 2025

Adverse events should be reported. Reporting forms and information can be found at www.mrha.gov.uk/yellowcard or search for MHRA yellow card in the Google Play or in the Apple App Store.
Adverse events should also be reported to Cambridge Healthcare Supplies Ltd at +44(0)330 1359 434 or medinfo@cambridge-healthcare.co.uk